Virus infection inhibitor and virus infection inhibition product

Abstract

Provided is a virus infection inhibitor capable of exhibiting an excellent virus infection inhibiting effect. The virus infection inhibitor according to the present invention comprises a compound of a salt having a sulfonic acid group and an organic acid, and preferably, the solubility of the organic acid in water at 25 DEG C is 20 g / L or less, so that the virus infection inhibitor has an excellent virus infection inhibition effect on both a virus having an envelope and a virus not having an envelope, and exhibits a virus infection inhibition effect on various viruses.

Description

[0001] This application is a divisional application based on a patent application with an application date of March 11, 2022, a priority date of March 12, 2021, an application number of 202280019798.7, and an invention name of "Viral infection inhibitors and viral infection inhibition products". Technical Field

[0002] The present invention relates to a viral infection inhibitor and a viral infection inhibiting product. Background Art

[0003] In recent years, in addition to the epidemic of seasonal influenza viruses, the new coronavirus (COVID-19) is spreading worldwide.

[0004] In addition, the highly pathogenic avian influenza virus has mutated and has been confirmed to be transmitted from person to person. In addition, there are concerns about the SARS virus with an extremely high mortality rate, and the sense of insecurity about viruses is increasing.

[0005] In view of these problems, Patent Document 1 proposes an antiviral synthetic resin composition containing 0.5 parts by weight or more of a sulfonic acid-based surfactant based on 100 parts by weight of the synthetic resin.

[0006] Prior art literature

[0007] Patent Literature

[0008] Patent Document 1: Japanese Patent Application Publication No. 2016-128395 Summary of the invention

[0009] Technical problem to be solved by the invention

[0010] However, the antiviral synthetic resin composition merely contains a sulfonic acid surfactant in a synthetic resin, but the sulfonic acid surfactant does not have sufficient antiviral property (viral infection inhibitory effect), and a viral infection inhibitor having an excellent viral infection inhibitory effect is desired.

[0011] The present invention provides a virus infection inhibitor capable of exerting an excellent virus infection inhibitory effect.

[0012] Technical means to solve technical problems

[0013] The virus infection inhibitor of the present invention comprises a compound having a salt of a sulfonic acid group and an organic acid.

[0014] The viral infection inhibiting product of the present invention comprises: a base material, and the viral infection inhibiting agent contained in the base material.

[0015] Effects of the Invention

[0016] The virus infection inhibitor of the present invention comprises a compound having a salt of a sulfonic acid group and an organic acid, and therefore has an excellent virus infection inhibitory effect on both enveloped viruses and non-enveloped viruses, and exhibits a virus infection inhibitory effect on various viruses. DETAILED DESCRIPTION

[0017] The virus infection inhibitor of the present invention contains a compound having a salt of a sulfonic acid group and an organic acid as active ingredients.

[0018] [Compound having a salt of a sulfonic acid group]

[0019] The compound having a salt of a sulfonic acid group is a salt having a sulfonic acid group in the molecule. The compound having a salt of a sulfonic acid group is derived from a salt containing a sulfonic acid group (-SO 3 X: X is a metal element or NH 4 + ) molecular structure part and exert virus infection inhibition effect. Compounds having salts of sulfonic acid groups have excellent virus infection inhibition effect on enveloped viruses in particular. It should be noted that compounds having salts of sulfonic acid groups may have carboxyl groups (-COOH), thiol groups (-SH) and hydroxyl groups (-OH).

[0020] The salt of the sulfonic acid group is not particularly limited, and examples thereof include sodium salts, calcium salts, ammonium salts, magnesium sulfonate salts, and barium sulfonate salts. Among them, sodium salts are preferred.

[0021] The compound having a salt of a sulfonic acid group is preferably an organic compound. In the present invention, the organic compound refers to a compound containing at least one (preferably two or more) carbon atoms in the molecule and containing a carbon-hydrogen bond (CH bond).

[0022] When the salt compound having a sulfonic acid group is an organic compound, the affinity with the organic acid described later is improved, so that the salt compound having a sulfonic acid group and the organic acid are close, the interaction between the salt compound having a sulfonic acid group and the organic acid is improved, and the viral infection inhibitory effect on both viruses without an envelope (non-enveloped viruses) and viruses with an envelope (enveloped viruses) is improved.

[0023] In addition, when the virus infection inhibitor is attached to the surface of the resin particles and used, if the compound having a salt of a sulfonic acid group is an organic compound, the compound having a salt of a sulfonic acid group has hydrophobicity in the organic chain part (hydrophobic part) represented by the carbon-hydrogen bond part. The organic chain part of the compound having a salt of a sulfonic acid group has excellent affinity with the resin particles, while the salt of a sulfonic acid group having a lower affinity than the organic chain part tends to face outward with respect to the resin particles, and can more effectively exert the virus infection inhibitory effect.

[0024] The compound of the salt having a sulfonic acid group preferably has an aromatic ring. When the compound of the salt having a sulfonic acid group has an aromatic ring, the affinity with the organic acid is improved, so that the compound of the salt having a sulfonic acid group is close to the organic acid, the interaction between the compound of the salt having a sulfonic acid group and the organic acid is improved, and the inhibitory effect on both enveloped viruses and non-enveloped viruses is improved.

[0025] When a virus infection inhibitor or a compound having a salt of a sulfonic acid group constituting the virus infection inhibitor is attached to the surface of a resin particle for use, if the compound having a salt of a sulfonic acid group has an aromatic ring, the compound having a salt of a sulfonic acid group is maintained firmly attached to the surface of the resin particle due to the affinity between the aromatic ring and the synthetic resin constituting the resin particle, thereby suppressing the detachment of the compound having a salt of a sulfonic acid group, and enabling the virus infection inhibitor to maintain an excellent virus infection inhibition effect for a long time.

[0026] The aromatic ring may be a monocyclic aromatic ring or a ring formed by combining and condensing monocyclic aromatic rings (condensed aromatic ring). The aromatic ring is not particularly limited, and examples thereof include benzene ring, naphthalene ring, anthracene ring, biphenyl, phenoxyphenyl, etc., preferably benzene ring and naphthalene ring. In the case of the aromatic ring, any one or more hydrogen atoms in the aromatic ring and the condensed aromatic ring are removed and bonded to other atoms through covalent bonds.

[0027] In the compound having a salt of a sulfonic acid group, the sulfonic acid group is preferably directly or indirectly bonded to an aromatic ring, and more preferably directly bonded to an aromatic ring. Due to the affinity between the aromatic ring of the compound having a salt of a sulfonic acid group and the organic acid, the compound having a salt of a sulfonic acid group and the organic acid are brought close to each other, and the synergistic effect of the salt of the sulfonic acid group of the compound having a salt of a sulfonic acid group and the organic acid can be improved, and the viral infection inhibitory effect on both enveloped viruses and non-enveloped viruses can be improved.

[0028] In the compound having a salt of a sulfonic acid group, when the salt of the sulfonic acid group is indirectly bonded to the aromatic ring, the salt of the sulfonic acid group is preferably bonded to the aromatic ring via an alkylene group (preferably a methylene group or an ethylene group) having 1 to 4 carbon atoms. While maintaining the affinity between the aromatic ring and the organic acid in the compound having a salt of a sulfonic acid group, the salt of the sulfonic acid group is appropriately separated from the aromatic ring by the alkylene group, and the salt of the sulfonic acid group can be oriented in a state where it is further exposed, so that the viral infection inhibitor exerts an excellent viral infection inhibitory effect.

[0029] The compound having a salt of a sulfonic acid group is not particularly limited as long as it has one or more sulfonic acid groups in the molecule, and examples thereof include linear alkylbenzene sulfonates, α-olefin sulfonates, alkyl diphenyl ether sulfonates, polyoxyalkylene alkyl ether sulfate salts, and polymers having a salt of a sulfonic acid group in a side chain of a linear polymer.

[0030] Examples of the linear alkylbenzene sulfonate include sodium dodecylbenzene sulfonate, calcium dodecylbenzene sulfonate, ammonium dodecylbenzene sulfonate, magnesium dodecylbenzene sulfonate, barium dodecylbenzene sulfonate, sodium tridecylbenzene sulfonate, ammonium tridecylbenzene sulfonate, sodium tetradecylbenzene sulfonate, and ammonium tetradecylbenzene sulfonate. Sodium dodecylbenzene sulfonate is preferred.

[0031] The number of carbon atoms in the alkyl group of the linear alkylbenzene sulfonate is preferably 10 or more, more preferably 11 or more, and more preferably 12 or more. The number of carbon atoms in the alkyl group of the linear alkylbenzene sulfonic acid is preferably 25 or less, more preferably 20 or less, and more preferably 18 or less. When the number of carbon atoms in the alkyl group is within the above range, the compound having a salt of a sulfonic acid group and the organic acid are brought into proximity due to the affinity between the hydrophobic part derived from the alkyl group and the organic acid, and the synergistic effect of the salt of the sulfonic acid group of the compound having a salt of a sulfonic acid group and the organic acid can be enhanced, and the inhibitory effect on both enveloped viruses and non-enveloped viruses can be enhanced.

[0032] Examples of the α-olefin sulfonate include C12-C18 sodium olefin sulfonate, C12-C18 calcium olefin sulfonate, C12-C18 ammonium olefin sulfonate, C12-C18 magnesium olefin sulfonate, C12-C18 barium olefin sulfonate, and preferably C14 sodium tetradecene sulfonate.

[0033] The carbon number of the α-olefin in the α-olefin sulfonate is preferably 12 or more, more preferably 14 or more. The carbon number of the α-olefin in the α-olefin sulfonate is preferably 22 or less, more preferably 18 or less. When the carbon number of the α-olefin is within the above range, the affinity between the hydrophobic part derived from the α-olefin chain of the compound having a salt of a sulfonic acid group and the organic acid makes the compound having a salt of a sulfonic acid group close to the organic acid, and the synergistic effect of the salt of the sulfonic acid group of the compound having a salt of a sulfonic acid group and the organic acid can be enhanced, and the viral infection inhibitory effect on both enveloped viruses and non-enveloped viruses can be enhanced.

[0034] Examples of the alkyl diphenyl ether sulfonate include sodium salts, calcium salts, ammonium salts, magnesium salts, and barium salts of alkyl phenyl ethers having an alkyl group of C6 to C18, and sodium dodecyl diphenyl ether sulfonate having C12 is preferred.

[0035] The number of carbon atoms in the alkyl diphenyl ether sulfonate is preferably 8 or more, more preferably 10 or more. The number of carbon atoms in the alkyl diphenyl ether sulfonate is preferably 24 or less, more preferably 18 or less. When the number of carbon atoms in the alkyl group is within the above range, the hydrophobic part of the alkyl group of the compound having a salt of a sulfonic acid group and the affinity of the organic acid make the compound having a salt of a sulfonic acid group approach the organic acid, and the synergistic effect of the salt of the sulfonic acid group of the compound having a salt of a sulfonic acid group and the organic acid can be enhanced, and the viral infection inhibitory effect on both enveloped viruses and non-enveloped viruses can be enhanced.

[0036] Among the linear polymers having a salt of a sulfonic acid group in a side chain, the linear polymer is not particularly limited, but is preferably a vinyl polymer, a polyester, or a polyurethane, and preferably a vinyl polymer.

[0037] The polymer having a salt of a sulfonic acid group on the side chain of the linear polymer is not particularly limited, and examples thereof include a polymer containing a styrene sulfonate component, a styrene sulfonate homopolymer, a styrene-styrene sulfonate copolymer, a sulfonate of a compound obtained by sulfonating the benzene ring of polystyrene, and a sulfonate of a compound obtained by sulfonating the benzene ring of a polymer containing a styrene component.

[0038] In addition, the polymer having a salt of a sulfonic acid group on the side chain of the linear polymer is preferably a homopolymer or copolymer of a monomer having a salt of a sulfonic acid group. Examples of the monomer having a salt of a sulfonic acid group include sodium p-styrene sulfonate, sodium m-styrene sulfonate, sodium o-styrene sulfonate, calcium p-styrene sulfonate, calcium m-styrene sulfonate, calcium o-styrene sulfonate, ammonium p-styrene sulfonate, ammonium m-styrene sulfonate, ammonium o-styrene sulfonate, sodium naphthalene sulfonate, and calcium naphthalene sulfonate. Sodium styrene sulfonate is preferred, and sodium p-styrene sulfonate is more preferred from the perspective of less steric hindrance in terms of reactivity with viruses.

[0039] It should be noted that the monomer having the salt of the sulfonic acid group can form a copolymer with other monomers. Examples of copolymerizable monomers include alkyl acrylates, alkyl methacrylates, vinyl alkyl ethers, vinyl acetate, ethylene, propylene, butylene, butadiene, diisobutylene, vinyl chloride, vinylidene chloride, 2-vinylnaphthalene, styrene, acrylonitrile, acrylic acid, sodium acrylate, methacrylic acid, maleic acid, fumaric acid, maleic anhydride, acrylamide, methacrylamide, diacetone acrylamide, vinyl toluene, xylene sulfonic acid, vinyl pyridine, vinyl sulfonic acid, vinyl alcohol, methyl methacrylate, sodium methacrylate, hydroxyethyl methacrylate, and the like, preferably styrene.

[0040] A polymer having a salt of a sulfonic acid group on the side chain of a linear polymer can be produced by a general method, for example: a method of subjecting a monomer having a salt of a sulfonic acid group to free radical polymerization; a method of subjecting a monomer having a salt of a sulfonic acid group to free radical polymerization with a monomer copolymerizable with the monomer; a method of neutralizing the sulfonic acid of a polymer containing a monomer component having a salt of a sulfonic acid group using an alkali (such as sodium hydroxide, calcium hydroxide, potassium hydroxide, ammonium hydroxide, etc.), etc.

[0041] [Organic acid]

[0042] The virus infection inhibitor contains an organic acid. By making the virus infection inhibitor contain an organic acid, the release of the salt of the sulfonic acid group in the compound having the salt of the sulfonic acid group can be promoted, the virus infection inhibitor effect on non-enveloped viruses can be improved, and the virus infection inhibitor effect on enveloped viruses and non-enveloped viruses can be improved.

[0043] In addition, the compound having a salt of a sulfonic acid group can weaken the capsid (protein shell) of a non-enveloped virus, thereby enhancing the effect of the organic acid on inhibiting viral infection of the non-enveloped virus.

[0044] As described above, the virus infection inhibitor contains a compound having a salt of a sulfonic acid group and an organic acid, and thus has an enhanced effect of inhibiting virus infection against enveloped viruses and non-enveloped viruses.

[0045] The organic acid may be any organic compound as long as it can promote the release of a part or all of the sulfonic acid group salts in the compound having the sulfonic acid group salts, and may be a polymer. The organic acid has a carboxyl group (-COOH), a sulfonic acid group (-SO 3 H), thiol group (-SH) or hydroxyl group (-OH), and may have only one of these functional groups or may have multiple functional groups. Since organic acid can more effectively maintain or promote the release of a part or all of the salts of the sulfonic acid groups in the compound having the salt of the sulfonic acid group, it can further improve the viral infection inhibitory effect on enveloped viruses and non-enveloped viruses, so it is preferred to have a carboxyl group.

[0046] The organic acid preferably has a plurality of carboxyl groups (-COOH), sulfonic acid groups (-SO 3 H), thiol (-SH) and hydroxyl (-OH), and more preferably have multiple carboxyl groups. When the organic acid has multiple such functional groups, it is possible to more reliably maintain or promote the release of a portion or all of the salts of the sulfonic acid groups in the compound having the salt of the sulfonic acid group, and further improve the viral infection inhibitory effect on enveloped viruses and non-enveloped viruses. It should be noted that the organic acid preferably does not contain a salt of the sulfonic acid group.

[0047] As an organic acid, any acid having a carboxyl group (-COOH), a sulfonic acid group (-SO 3H), thiol group (-SH) or hydroxyl group (-OH), but there is no particular limitation, and examples thereof include adipic acid (solubility: 14 g / L), benzoic acid (solubility: 3.4 g / L), lauric acid (solubility: 0 g / L), azelaic acid (solubility: 2.4 g / L), sebacic acid (solubility: 0.25 g / L), dodecanedioic acid (solubility: 0 g / L), fumaric acid (solubility: 6.3 g / L), phthalic acid (solubility: 7.2 g / L), isophthalic acid (solubility: 0.13 g / L), terephthalic acid (solubility: 0.017 g / L), methylenedisalicylic acid (solubility: 0 g / L), cis-Δ4-tetrahydrophthalic acid (solubility: 0 g / L), hexanoic acid (solubility: 11 g / L), heptanoic acid (solubility: 2.4 g / L), octanoic acid (solubility: 0.6 8g / L), nonanoic acid (solubility: 0.28g / L), capric acid (solubility: 0.15g / L), lauric acid (solubility: 0.0048g / L), myristic acid (solubility: 0g / L), palmitic acid (solubility: 0g / L), stearic acid (solubility: 0g / L), myristic acid (solubility: 0g / L), oleic acid (solubility: 0g / L), ricinoleic acid (solubility: 0g / L), salicylic acid (solubility: 2.0g / L), gallic acid hydrate (solubility: 11g / L), benzilic acid (solubility: 1.4g / L), 4-aminobenzoic acid (solubility: 6g / L), nitrilotriacetic acid (solubility: 1.3g / L), polyacrylic acid (solubility: 250g / L or more), etc., preferably adipic acid, fumaric acid, phthalic acid, benzoic acid, and more preferably adipic acid and benzoic acid. It should be noted that the organic acid may be used alone or in combination of two or more. It should be noted that the solubility described in parentheses is the solubility of the organic acid in water at 25°C.

[0048] The solubility of the organic acid in water at 25°C is preferably 20 g / L or less, more preferably 18 g / L or less. When the solubility of the organic acid in water at 25°C is 20 g / L or less, the hydrophobicity of the compound having a salt of a sulfonic acid group is improved, and the affinity with the organic acid is improved, so that the compound having a salt of a sulfonic acid group is close to the organic acid, and the synergistic effect of the salt of the sulfonic acid group of the compound having a salt of a sulfonic acid group and the organic acid can be improved, and the viral infection inhibitory effect on both enveloped viruses and non-enveloped viruses can be improved. It should be noted that the solubility of the organic acid in water at 25°C refers to the mass of the organic acid dissolved in 1L of water.

[0049] The solubility of the organic acid in water at 25° C. is preferably 0.1 g / L or more, more preferably 1 g / L or more. When the solubility of the organic acid in water at 25° C. is 0.1 g / L or more, when the organic acid comes into contact with an aqueous protein solution containing viruses such as saliva and sputum, the release of the salt of the sulfonic acid group in the compound having the salt of the sulfonic acid group is promoted, and the effect of inhibiting viral infection of non-enveloped viruses is improved.

[0050] The pKa of the organic acid at 25°C is preferably 5.5 or less, more preferably 4.6 or less, and more preferably 3.8 or less. When the pKa of the organic acid at 25°C is 5.5 or less, the synergistic effect of the salt of the sulfonic acid group and the organic acid improves the inhibitory effect on the viral infection of enveloped viruses. When it is 3.8 or less, the protein denaturation caused by protons is caused by further promoting the release of the salt of the sulfonic acid group, and the inhibitory effect not only on enveloped viruses but also on non-enveloped viruses is improved. It should be noted that the pKa of the organic acid refers to the value measured by titration at 25°C. Specifically, the organic acid and sodium hydroxide are titrated at 25°C, and the pH at 25°C at the half-equivalent point (the point where half of the amount of the dropwise neutralization is completed) is measured, thereby the pKa can be calculated.

[0051] When the organic acid is a polymer, the weight average molecular weight of the organic acid is preferably 3000 or more, preferably 5000 or more, more preferably 10000 or more, and more preferably 100000 or more. When the weight average molecular weight of the organic acid is 3000 or more, the whitening and yellowing of the virus infection inhibitor can be reduced, and when the virus infection inhibitor is attached to the surface of the substrate, the virus infection inhibitor can be more effectively exhibited without damaging the appearance of the substrate, and the adsorption points of each organic acid molecule and the virus are increased, so that the interaction between the organic acid and the virus is enhanced, and the virus infection inhibitor can improve the virus infection inhibitor effect.

[0052] The weight average molecular weight of the organic acid is preferably 1,000,000 or less, more preferably 900,000 or less, more preferably 800,000 or less, and more preferably 500,000 or less. When the weight average molecular weight of the organic acid is 1,000,000 or less, yellowing of the virus infection inhibitor can be reduced, and when the virus infection inhibitor is attached to the surface of the substrate, the virus infection inhibitor can more effectively exhibit the virus infection inhibitory effect without damaging the appearance of the substrate, and the cohesion of the organic acid is reduced, resulting in a form in which the organic acid and the virus easily interact with each other, so that the virus infection inhibitor The virus infection inhibitor's effect is improved.

[0053] In addition, in this invention, the weight average molecular weight of a polymer is the value measured by the GPC (gel permeation chromatography) method in terms of polystyrene.

[0054] For example, the measurement can be performed using the following measurement apparatus and measurement conditions.

[0055] Gel Permeation Chromatograph: Trade name "2690 Separations Model" manufactured by Waters Corporation

[0056] Column: Showa Denko trade name "GPC KF-806L"

[0057] Detector: Differential Refractometer

[0058] Sample flow rate: 1mL / min

[0059] Column temperature: 40°C

[0060] Eluent: THF

[0061] The organic acid may be in the form of particles. The D90 particle size of the particulate organic acid is preferably 2 μm or more, more preferably 2.5 μm or more, more preferably 3 μm or more, and more preferably 3.5 μm or more. The D90 particle size of the organic acid is preferably 25 μm or less, more preferably 22 μm or less, more preferably 20 μm or less, more preferably 18 μm or less, more preferably 16 μm or less, more preferably 14 μm or less, and more preferably 12 μm or less. When the D90 particle size is 2 μm or more, the overall surface area of ​​the organic acid becomes smaller, the cohesion of the viral infection inhibitor decreases, and the organic acid and the virus easily interact in a form, thereby improving the viral infection inhibitory effect of the viral infection inhibitor. When the D90 particle size is 25 μm or less, the aggregation of the viral infection inhibitor can be prevented and the surface area can be increased to facilitate contact with the virus, thereby improving the viral infection inhibitory effect of the viral infection inhibitor, and the functional groups [carboxyl (-COOH), sulfonic acid (-SO 3 H), thiol group (-SH) and / or hydroxyl group (-OH)] and the resulting whitening due to the crystallization of the organic acid caused by the interaction between them.

[0062] As described later, the D90 particle size of the particulate organic acid is the particle size (90% cumulative particle size) at which the accumulation of frequencies in the volume-based particle size distribution based on the laser scattering method (accumulation starting from particles with a small particle size) reaches 90%. The D90 particle size of the organic acid is preferably adjusted to 2 to 25 μm, and the particle size of particles with a large particle size in the organic acid is adjusted to a given range, thereby reducing the situation where the organic acid contains coarse particles. The organic acid has functional groups [carboxyl (-COOH), sulfonic acid (-SO 3 H), thiol group (-SH) and / or hydroxyl group (-OH)], by adjusting the particle size of the organic acid to the above range, the amount of the functional groups present in the organic acid is adjusted, thereby imparting an excellent viral infection inhibitory effect to the viral infection inhibitor, and reducing the whitening caused by the crystallization of the organic acid caused by the interaction between the functional groups possessed by the organic acid.

[0063] The D50 particle size of the particulate organic acid is preferably 0.5 μm or more, more preferably 1 μm or more, more preferably 1.5 μm or more, more preferably 2.0 μm or more. The D50 particle size of the particulate organic acid is preferably 14 μm or less, more preferably 12 μm or less, more preferably 11 μm or less.

[0064] In the particulate organic acid, by setting the D50 particle size to the range (preferably 0.5 to 14 μm) and the D90 particle size to 2 to 25 μm, the situation where the organic acid contains coarse particles having a particle size far away from the D50 particle size can be reduced, and the particle size of the organic acid can be made into a more appropriate size.

[0065] Furthermore, by adjusting the particle size of the organic acid to a more appropriate range, the amount of the functional groups present on the surface of the organic acid can be more appropriately adjusted, thereby more effectively imparting an excellent viral infection inhibitory effect to the viral infection inhibitor, and more effectively reducing whitening caused by crystallization of the organic acid due to the interaction between the functional groups possessed by the organic acid.

[0066] The D90 particle size and D50 particle size of the organic acid refer to the particle size (90% cumulative particle size and 50% cumulative particle size) at which the accumulation of frequencies in the volume-based particle size distribution based on the laser scattering method reaches 90% and 50%, respectively. When the organic acid includes a plurality of organic acids, the D90 particle size and D50 particle size of the organic acid are values ​​measured based on the organic acid as a whole.

[0067] The organic acid is preferably solid at 1 atmosphere (1013.25 hPa) and 25° C. When the organic acid is solid at 1 atmosphere and 25° C., it is easy to appear on the surface of the virus infection inhibiting product such as the processed coating film, and is easy to contact with the virus, so that the virus infection inhibiting effect is improved.

[0068] In the viral infection inhibitor, the content of the organic acid is preferably 5 parts by mass or more, more preferably 10 parts by mass or more, and more preferably 20 parts by mass or more relative to 100 parts by mass of the compound having a salt of a sulfonic acid group. When the content of the organic acid is 5 parts by mass or more, the release of a part of the salt of the sulfonic acid group in the compound having a salt of a sulfonic acid group can be more reliably maintained or promoted, and the viral infection inhibitory effect on enveloped viruses and non-enveloped viruses can be further improved.

[0069] In the viral infection inhibitor, the content of the organic acid is preferably 8000 parts by mass or less, more preferably 6000 parts by mass or less, and more preferably 4000 parts by mass or less relative to 100 parts by mass of the compound having a salt of a sulfonic acid group. When the content of the organic acid is 8000 parts by mass or less, the viral infection inhibitory effect on enveloped viruses and non-enveloped viruses can be further improved by the synergistic effect of the compound having a salt of a sulfonic acid group and the organic acid.

[0070] [Viral infection inhibitors]

[0071] The viral infection inhibitor contains a salt compound having a sulfonic acid group and an organic acid (excluding a compound having a sulfonic acid group) as active ingredients. The method for producing the viral infection inhibitor is not particularly limited. The viral infection inhibitor can be produced by uniformly mixing a salt compound having a sulfonic acid group and an organic acid (excluding a compound having a sulfonic acid group) in a general manner.

[0072] It should be noted that the virus infection inhibitory effect refers to the effect of eliminating or reducing the infectivity of the virus to the cell, or preventing the virus from proliferating in the cell even if infected. As a method for confirming the presence or absence of such virus infectivity, for example, ISO18184 and JISL1922 can be cited for fiber products, and ISO21702 can be cited for plastics other than fiber products and products with non-porous surfaces. The Antimicrobial Products Technology Association (SIAA) certifies the antiviral processing mark for products that meet the safety standards of antiviral processing agents and certain antiviral effect standards. The standard for antiviral effect is: in the evaluation of ISO21702, the difference (antiviral activity value) between the common logarithm of the virus infection titer of the blank product (antiviral processing agent without additives) and the common logarithm of the virus infection titer of the processed product (antiviral processing agent additives) is 2.0 or more. The virus infection inhibitor is used as a component of the antiviral processing agent, mixed in a resin or added to a surface coating agent such as a paint, and is evaluated by the above evaluation method.

[0073] In the present invention, for example, when evaluating the virus infection inhibitory effect under the following conditions, a product whose difference in the common logarithmic value of the virus infection titer between the blank product and the processed product (antiviral activity value) is 2.0 or more is defined as a virus infection inhibitor. At this time, regardless of the type of virus to be evaluated, in at least one virus, a product whose difference in the common logarithmic value of the virus infection titer between the blank product and the processed product (antiviral activity value) is 2.0 or more is treated as a virus infection inhibitor.

[0074] 50 mg of a virus infection inhibitor was added to 950 mg of a solvent-free ultraviolet curable acrylic resin (trade name "Teslack 2328" manufactured by Hitachi Chemical Co., Ltd.) and uniformly mixed to prepare a coating. The obtained coating was applied on a polyester film and then irradiated with a light intensity of 512 mJ / cm using a UV delivery device EYE GRANDAGE (manufactured by EYE GRAPHICS Co., Ltd., irradiator reflector: cold mirror condenser type, UV lamp: H03-L31 (light emission length 250 mm)). 2 The ultraviolet rays were irradiated to cure the ultraviolet curable acrylic resin to form a coating film with a film thickness of 15 μm to prepare a test coating film.

[0075] The antiviral test of the obtained test film was carried out according to ISO21702. The virus infection titer of the test film was calculated by the plaque method for the virus suspension after the reaction. A blank film was prepared in the same manner as described, except that the virus infection inhibitor was not included, and the virus infection titer (common logarithm) (PFU / cm 2 ). The difference in the common logarithmic values ​​of the virus infection titers (antiviral activity value) was calculated by subtracting the virus infection titer of the test coating from the virus infection titer of the blank coating.

[0076] In addition, the plaque method and hemagglutination titer (HAU) measurement method described in "Medical Virology" (first edition published in April 1990) can be cited.

[0077] The virus infection inhibitor has a virus infection inhibitory effect on various viruses due to the synergistic effect of the compound having a salt of a sulfonic acid group and an organic acid (excluding the compound having a sulfonic acid group), and exhibits an excellent virus infection inhibitory effect on both enveloped viruses and non-enveloped viruses.

[0078] Examples of enveloped viruses include influenza virus (e.g., type A, type B, etc.), rubella virus, Ebola virus, coronavirus [e.g., SARS virus, novel coronavirus (SARS-CoV-2)], measles virus, varicella-zoster virus, herpes simplex virus, mumps virus, arbovirus, RS virus, hepatitis virus (e.g., hepatitis B virus, hepatitis C virus, etc.), yellow fever virus, HIV, rabies virus, hantavirus, dengue virus, Nipah virus, lyssa virus, etc.

[0079] Examples of the non-enveloped virus include adenovirus, norovirus, rotavirus, human papillomavirus, poliovirus, enterovirus, coxsackievirus, human parvovirus, encephalomyocarditis virus, poliovirus, and ranavirus.

[0080] The virus infection inhibitor preferably makes the compound or organic acid constituting the salt with sulfonic acid group present on the surface of resin particles for use. The virus infection inhibitor preferably makes the compound or organic acid constituting the salt with sulfonic acid group adhere (carry) on the surface of resin particles for use. In addition, the virus infection inhibitor more preferably makes the compound and organic acid constituting the salt with sulfonic acid group adhere (carry) on the surface of particles for use. By making the compound or organic acid constituting the salt with sulfonic acid group of the virus infection inhibitor at least adhere to the surface of the particle, the virus infection inhibitor can be uniformly dispersed in the substrate described later without becoming a mass. Therefore, the surface area of ​​the virus infection inhibitor can be increased, and the contact of the virus infection inhibitor with the virus can be fully ensured, and the virus infection inhibitor can give full play to the virus infection inhibitor.

[0081] As particles that attach a virus infection inhibitor, a compound having a salt of a sulfonic acid group, or an organic acid to the surface, there is no particular limitation as long as the virus infection inhibitor's virus infection inhibitor effect is not hindered. As particles that attach a virus infection inhibitor, a compound having a salt of a sulfonic acid group, or an organic acid to the surface, resin particles and inorganic particles are preferred. As synthetic resins constituting resin particles, for example, there can be cited: styrene resins, acrylic resins, polyurethane resins, vinyl chloride resins, ABS resins; synthetic rubbers such as styrene-butadiene rubber (SBR), nitrile-butadiene rubber (NBR), etc., preferably containing acrylic resins or styrene resins, more preferably containing styrene resins, and more preferably containing polystyrene. It should be noted that the synthetic resin can be used alone or in combination of two or more.

[0082] The content of the acrylic resin in the resin particles is preferably 50% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 100% by mass or more.

[0083] The content of the styrene-based resin in the resin particles is preferably 50% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 100% by mass or more.

[0084] There are no particular limitations on the styrene-based resins, and examples thereof include: homopolymers or copolymers containing, as monomer units, styrene, methylstyrene, ethylstyrene, isopropylstyrene, dimethylstyrene, chlorostyrene, bromostyrene and other styrene-based monomers; copolymers containing, as monomer units, a styrene-based monomer and one or more vinyl monomers copolymerizable with the styrene-based monomer; and the like.

[0085] Examples of the vinyl monomer copolymerizable with the styrene-based monomer include acrylic monomers such as acrylonitrile, methacrylonitrile, acrylic acid, methacrylic acid, acrylic acid esters (methyl acrylate, ethyl acrylate, butyl acrylate, etc.), methacrylate esters (methyl methacrylate, ethyl methacrylate, butyl methacrylate, etc.), maleic anhydride, and acrylamide.

[0086] The synthetic resin constituting the resin particles preferably contains an aromatic ring. The aromatic ring plays a role in attracting the hydrophobic part of the compound having a salt of a sulfonic acid group attached to the surface of the resin particles, orienting the hydrophilic salt of the sulfonic acid group toward the outside, and can more effectively exert the virus infection inhibitory effect of the virus infection inhibitor.

[0087] As the inorganic material constituting the inorganic particles, there is no particular limitation, and for example, there can be mentioned: silicon dioxide, silica gel, zeolite, hydrotalcite, calcium carbonate, calcium citrate, magnesium carbonate, magnesium hydroxide, diatomaceous earth, kaolin, talc, aluminum hydroxide, titanium oxide, calcium phosphate, calcium sulfate, magnesium carbonate, zinc oxide, manganese oxide, iron oxide, aluminum oxide, barium sulfate, zirconium oxide, tungsten oxide, zirconium phosphate, zirconium carbide, glass, calcium silicate, aluminum silicate, silicon carbide, activated carbon, tobermorite, montmorillonite, bentonite, iron, tin, aluminum, zinc, copper, titanium, nickel, various alloys, etc. It should be noted that the inorganic material can be used alone or in combination of two or more.

[0088] The D50 particle size of the particles is preferably 0.1 μm or more, more preferably 1 μm or more. The D50 particle size of the particles is preferably 30 μm or less, more preferably 15 μm or less. When the D50 particle size of the particles is 0.1 μm or more, the surface area of ​​the particles becomes smaller, the cohesion of the viral infection inhibitor decreases, and the viral infection inhibitor becomes a form that easily interacts with the virus, thereby improving the viral infection inhibition effect. If the D50 particle size of the particles is 30 μm or less, the aggregation of the viral infection inhibitor is prevented and the surface area is increased to facilitate contact with the virus, thereby improving the viral infection inhibition effect of the viral infection inhibitor.

[0089] The D50 particle size of a particle refers to the particle size (50% cumulative particle size) at which the accumulation of frequencies in the volume-based particle size distribution based on the laser scattering method (accumulation starting from particles with a small particle size) reaches 50%. When the particle contains multiple particles, the D50 particle size of the particle is a value measured based on the entire particle.

[0090] The amount of the virus infection inhibitor attached to the resin particles is preferably 1 part by mass or more, more preferably 5 parts by mass or more, more preferably 7 parts by mass or more, and more preferably 10 parts by mass or more, relative to 100 parts by mass of the resin particles. When the amount of the virus infection inhibitor attached is 1 part by mass or more, the virus infection inhibitor can be uniformly attached to the surface of the resin particles, and the virus infection inhibitor can more effectively exert its virus infection inhibitory effect.

[0091] The amount of the virus infection inhibitor attached to the resin particles is preferably 50 parts by mass or less, more preferably 40 parts by mass or less, more preferably 30 parts by mass or less, and more preferably 20 parts by mass or less, relative to 100 parts by mass of the resin particles. When the amount of the virus infection inhibitor attached is 50 parts by mass or less, the virus infection inhibitors do not bind to each other, the virus infection inhibitors are effectively arranged on the surface of the resin particles, and the virus infection inhibitory effect is improved.

[0092] The amount of the compound having a salt of a sulfonic acid group attached to the resin particles is preferably 1 part by mass or more, more preferably 5 parts by mass or more, more preferably 7 parts by mass or more, and more preferably 10 parts by mass or more, relative to 100 parts by mass of the resin particles. When the amount of the compound having a salt of a sulfonic acid group attached is 1 part by mass or more, the compound having a salt of a sulfonic acid group can be uniformly attached to the surface of the resin particles, and the viral infection inhibitor can more effectively exert its viral infection inhibitory effect.

[0093] The amount of the compound having a salt of a sulfonic acid group attached to the resin particles is preferably 50 parts by mass or less, more preferably 40 parts by mass or less, more preferably 30 parts by mass or less, and more preferably 20 parts by mass or less, relative to 100 parts by mass of the resin particles. When the amount of the compound having a salt of a sulfonic acid group attached is 50 parts by mass or less, the compounds having a salt of a sulfonic acid group do not bond to each other, the compounds having a salt of a sulfonic acid group are effectively arranged on the surface of the resin particles, and the virus infection inhibitory effect is improved.

[0094] The method for attaching the virus infection inhibitor, the salt compound having a sulfonic acid group, or the organic acid to the surface of the resin particles is not particularly limited. For example, the virus infection inhibitor, the salt compound having a sulfonic acid group, or the organic acid can be attached to the surface of the resin particles by the adhesion force of the virus infection inhibitor, the salt compound having a sulfonic acid group, or the organic acid itself, or the virus infection inhibitor, the salt compound having a sulfonic acid group, or the organic acid can be attached to the surface of the resin particles using a binder resin. From the viewpoint of being able to effectively exert the virus infection inhibitory effect of the virus infection inhibitor, it is preferred that the virus infection inhibitor be attached to the surface of the resin particles by the adhesion force of the salt compound having a sulfonic acid group contained in the virus infection inhibitor itself.

[0095] The viral infection inhibitor is contained in a base material to which a viral infection inhibitor effect is to be imparted and used, and the base material containing the viral infection inhibitor exhibits the viral infection inhibitor effect as a viral infection inhibitor product.

[0096] The substrate containing the viral infection inhibitor is not particularly limited as long as it can contain the viral infection inhibitor, and examples thereof include: synthetic resin moldings, coatings, wallpapers, decorative sheets, floor materials, fiber products (woven fabrics, non-woven fabrics, knitted fabrics), interior products and interior materials (seats, child seats and foam bodies constituting them, etc.) for vehicles (such as cars, airplanes, ships, etc.), kitchen supplies, baby products, building interior materials, etc.

[0097] As the coating, conventionally known coatings can be used, for example, oily coatings (e.g., mixed coatings, oil varnishes, etc.), cellulose coatings, synthetic resin coatings, etc. can be cited. The coating can contain additives such as pigments, plasticizers, curing agents, extenders, fillers, anti-aging agents, tackifiers, surfactants, etc., within the range that does not damage its physical properties. It should be noted that as a method for including a viral infection inhibitor in the coating, for example, a method of supplying the viral infection inhibitor and the coating to a dispersing device and uniformly mixing them can be cited. Examples of dispersing devices include high-speed mills, ball mills, and sand mills.

[0098] The building interior material is not particularly limited, and examples thereof include floor materials, wallpapers, ceiling materials, paints, door handles, switches, switch covers, wax, and the like.

[0099] The vehicle interior products and vehicle interior materials are not particularly limited, and examples thereof include seats, child seats, seat belts, car mats, seat covers, doors, roof materials, floor mats, door trims, instrument panels, consoles, glove boxes, hanging rings, armrests, and the like.

[0100] Example

[0101] Hereinafter, the present invention will be described in more detail using Examples, but the present invention is not limited thereto.

[0102] [Preparation of carboxyl compounds 1 to 5]

[0103] The acrylic acid and methyl acrylate in the given amounts shown in Table 1 were mixed to obtain an acrylic monomer solution. 1-Hydroxycyclohexane-1-ylphenylketone (trade name "Omnirad 184" manufactured by IGM Resins BV) as a radical polymerization initiator in the given amount shown in Table 1 was added and dissolved in the obtained acrylic monomer solution to prepare a raw material composition.

[0104] The raw material composition was coated on a polyethylene film using a wire bar coater #14 to form a coating layer with a thickness of 35 μm. A UV delivery device (trade name "ECS301G1" manufactured by EYE GRAPHICS) was used to irradiate the coating layer with ultraviolet light of a wavelength of 365 nm at 25°C so that the accumulated light intensity was 2000 mJ / cm 2 , free radical polymerization is carried out to obtain carboxyl-containing compounds (polymers having carboxyl groups on the side chains of linear polymers) 1 to 5 as virus infection inhibitory compounds.

[0105] [Table 1]

[0106]

[0107] [Preparation of organic acid particles]

[0108] The organic acids shown in Table 2 were coarsely pulverized using a roll press (trade name "150 type" manufactured by SEISHIN ENTERPRISE) under the operating conditions of a rotation speed of 25 rpm and a pressure of 25 t, and then pulverized using a jet mill (trade name "SJ-500" manufactured by NISSHIN ENGINEERING) under the operating conditions of a supply rate and a compressed air pressure of 0.75 MPa shown in Table 2 to obtain particles of the organic acid. It should be noted that oleic acid cannot be granulated because its melting point is below room temperature (25° C.).

[0109] [Preparation of resin particles having carboxyl group-containing compound 2 attached to the surface]

[0110] 5 parts by mass of particles of carboxyl compound 2 and 10 parts by mass of polystyrene particles (primary particles) having a D50 particle size of 4 μm were supplied to 100 parts by mass of water, and powdered using a spray dryer with an atomizer rotation speed of 20000 rpm, so that all particles of carboxyl compound 2 were attached (supported) on the surface of polystyrene particles, and then pulverized using a jet mill device (trade name "SJ-500" manufactured by NISSHIN ENGINEERING) under the operating conditions of a raw material supply speed of 1 kg / h and a compressed air pressure of 0.75 MPa, to obtain resin particles with particles of carboxyl compound 2 attached to the surface. It should be noted that in Table 2, "resin particles with particles of carboxyl compound 2 attached to the surface" is recorded as "resin particles attached to carboxyl compound 2".

[0111] [Preparation of Inorganic Particles Having Carboxyl Group-Containing Compound 2 Attached to the Surface]

[0112] 5 parts by mass of particles of carboxyl compound 2 and 10 parts by mass of silica particles (primary particles) with a D50 particle size of 6 μm are supplied to 100 parts by mass of water, and a spray dryer is used to pulverize with an atomizer rotation speed of 20000 rpm, so that all particles of carboxyl compound 2 are attached (supported) on the surface of silica particles, and then a jet mill device (trade name "SJ-500" manufactured by NISSHIN ENGINEERING) is used to crush the particles under the operating conditions of a raw material supply speed of 1 kg / h and a compressed air pressure of 0.75 MPa to obtain silica particles with particles of carboxyl compound 2 attached to the surface. It should be noted that in Table 2, "silicon particles with particles of carboxyl compound 2 attached to the surface" is recorded as "inorganic particles attached to carboxyl compound 2".

[0113] (Examples 1 to 11, 16 to 20 and Comparative Example 1)

[0114] A virus infection inhibitor was prepared by uniformly mixing 100 parts by mass of the salt compound shown in Table 2 and 900 parts by mass of the organic acid particles shown in Table 2. Oleic acid was used without particle formation because its melting point was below room temperature (25° C.).

[0115] (Examples 12 to 15)

[0116] 50 parts by mass of the salt compound shown in Table 2 and 150 parts by mass of polystyrene particles (primary particles) having a D50 particle size of 4 μm were supplied to 800 parts by mass of water and powdered using a spray dryer (atomizer rotation speed: 20,000 rpm) so that the total amount of the salt compound was attached (supported) on the surface of the polystyrene particles. 100 parts by mass of the polystyrene particles to which the salt compound was attached (supported) and 900 parts by mass of the particles of the organic acid shown in Table 2 were uniformly mixed to prepare a virus infection inhibitor.

[0117] (Example 21)

[0118] 100 parts by mass of the salt compound shown in Table 2 and 900 parts by mass of the particles of the carboxyl group-containing compound 2 attached to resin particles shown in Table 2 were uniformly mixed to prepare a virus infection inhibitor.

[0119] (Example 22)

[0120] 100 parts by mass of the salt compound shown in Table 2 and 900 parts by mass of the particles of the carboxyl group-containing compound 2 attached to the inorganic particles shown in Table 2 were uniformly mixed to prepare a virus infection inhibitor.

[0121] (Comparative Example 2)

[0122] 100 parts by mass of sodium dodecylbenzenesulfonate was used as a virus infection inhibitor.

[0123] (Comparative Example 3)

[0124] 100 parts by mass of adipic acid particles were used as a virus infection inhibitor.

[0125] The obtained virus infection inhibitors were subjected to antiviral tests using influenza virus (enveloped virus) and feline calicivirus (non-enveloped virus). The results are shown in Table 3.

[0126] For the organic acids contained in the viral infection inhibitor, the melting point at 1 atmosphere, the solubility in water at 25°C, the pKa at 25°C, the molecular weight (the weight average molecular weight in the case of a polymer), the D90 particle size, and the D50 particle size are shown in Table 2. In addition, in Table 2, the "melting point at 1 atmosphere" and the "solubility in water at 25°C" are simply described as "melting point" and "solubility".

[0127] (Antiviral test)

[0128] 50 mg of a virus infection inhibitor was added to 950 mg of a solvent-free ultraviolet curable acrylic resin (trade name "Teslack 2328" manufactured by Hitachi Chemical Co., Ltd.) and uniformly mixed to prepare a coating. The obtained coating was applied on a polyester film and then irradiated with a light intensity of 512 mJ / cm using a UV conveying device EYE GRANDAGE [manufactured by EYE GRAPHICS Co., Ltd., irradiator reflector: cold mirror condenser type, UV lamp: H03-L31 (light emission length 250 mm)]. 2 The ultraviolet rays were applied to cure the ultraviolet curable acrylic resin to form a coating film with a thickness of 15 μm. It should be noted that when the virus infection inhibitor was attached (supported) to the polystyrene particles or silica particles, the virus infection inhibitor was adjusted to 50 mg.

[0129] The surface of the obtained coating film was impregnated with 1 mL of water into a flat square nonwoven fabric (trade name "KIMWIPE S-200" manufactured by NIPPON PAPER CRECIA) with a side of 10 cm, and the coating film surface was repeatedly rubbed 10 times with the nonwoven fabric to prepare a test coating film.

[0130] The obtained test coating was subjected to an antiviral test in accordance with ISO 21702. The virus infection titer of the test coating was calculated by a plaque method using the virus suspension after the reaction.

[0131] A blank coating was prepared in the same manner as described above except that the virus infection inhibitor was not included. Based on the blank coating, the virus infection titer (common logarithm) (PFU / cm 2The virus infection titer (common logarithm value) of the blank coating is 6.5 PFU / cm 2 .

[0132] The antiviral activity value was calculated by subtracting the virus infection titer of the test coating from the virus infection titer of the blank coating.

[0133] In the antiviral test conducted in the examples, in the method for measuring the virus infection titer described in the "Specifications for Carrying Out the Invention", the surface of the coating film was wiped with a nonwoven fabric impregnated with water, and the coating film after wiping was used as the test coating film.

[0134] Since the surface of the coating film is wiped with the nonwoven fabric, the virus infection inhibitory effect of the coating film is reduced. That is, in the examples, the virus test was performed under more stringent conditions. The antiviral activity value obtained in the examples is lower than the antiviral activity value obtained by the determination method described in the "Specific Implementation Method". Therefore, when the antiviral activity value obtained in the antiviral test of the examples is 2 or more, it can be judged that the virus infection inhibitor has a virus infection inhibitory effect.

[0135] (Haze value)

[0136] The test coating was prepared in the same manner as in the antiviral test. The haze of the obtained test coating was evaluated according to JIS K7361. The haze value (%) was measured using a haze meter (trade name "HM-150" manufactured by Murakami Color Research Institute Co., Ltd.) at room temperature of 25°C and relative humidity of 40%.

[0137] [Table 2]

[0138]

[0139] [Table 3]

[0140]

[0141] Industrial Applicability

[0142] The virus infection inhibitor of the present invention comprises a compound having a salt of a sulfonic acid group and an organic acid, and therefore has an excellent virus infection inhibitory effect on both enveloped viruses and non-enveloped viruses, and exhibits a virus infection inhibitory effect on various viruses.

[0143] By making the substrate contain the virus infection inhibitor of the present invention, an excellent virus infection inhibitory effect can be imparted to the substrate.

[0144] (CROSS-REFERENCE TO RELATED APPLICATIONS)

[0145] This application claims priority based on Japanese Patent Application No. 2021-040825 filed on March 12, 2021, the disclosure of which is incorporated into this specification by reference in its entirety.

Claims

1. A viral infection inhibitor, comprising: A compound having a salt of a sulfonic acid group, and Organic acid.

2. The viral infection inhibitor according to claim 1, wherein The solubility of the organic acid in water at 25°C is 20 g / L or less.

3. The viral infection inhibitor according to claim 1 or 2, wherein Organic acids have a carboxyl group.

4. The viral infection inhibitor according to claim 1 or 2, wherein The pKa of the organic acid at 25°C is 5.5 or less.

5. The viral infection inhibitor according to claim 1 or 2, wherein The pKa of the organic acid at 25°C is 4.6 or less.

6. The viral infection inhibitor according to claim 1 or 2, wherein The organic acid is a macromolecular weight and has a weight average molecular weight of 3,000 or more.

7. The viral infection inhibitor according to claim 1 or 2, wherein The organic acid is in the form of particles, with a D90 particle size of 2~25μm.

8. The viral infection inhibitor according to claim 1 or 2, wherein The compound having a salt of a sulfonic acid group has an aromatic ring.

9. The viral infection inhibitor according to claim 1 or 2, wherein The compound or organic acid having a salt of a sulfonic acid group is present on the surface of the particle.

10. The viral infection inhibitor according to claim 1 or 2, wherein The compound having a salt of a sulfonic acid group or the organic acid is attached to the surface of the particle.

11. The viral infection inhibitor according to claim 9, wherein The particles are resin particles or inorganic particles.

12. The viral infection inhibitor according to claim 11, wherein The resin particles include acrylic resin or styrene resin.

13. A viral infection inhibition product comprising: substrate; and The viral infection inhibitor according to claim 1 or 2, which is contained in the substrate.

Images